# Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer

> **NCT03794778** · PHASE4 · UNKNOWN · sponsor: **Women's Hospital School Of Medicine Zhejiang University** · enrollment: 396 (estimated)

## Conditions studied

- Efficacy and Safety

## Interventions

- **DRUG:** pegylated liposomal doxorubicin
- **DRUG:** paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03794778
- **Lead sponsor:** Women's Hospital School Of Medicine Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-19
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794778, "Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03794778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*